PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
41.42
+0.26 (+0.63%)
At close: 4:02PM EDT

41.40 -0.02 (-0.05%)
After hours: 5:18PM EDT

Stock chart is not supported by your current browser
Previous Close41.16
Open41.23
Bid41.40 x 800
Ask41.47 x 800
Day's Range41.07 - 41.47
52 Week Range32.32 - 41.64
Volume15,475,705
Avg. Volume20,149,007
Market Cap242.289B
Beta0.96
PE Ratio (TTM)11.06
EPS (TTM)3.74
Earnings DateOct 29, 2018 - Nov 2, 2018
Forward Dividend & Yield1.36 (3.33%)
Ex-Dividend Date2018-08-02
1y Target Est40.60
Trade prices are not sourced from all markets
  • FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
    Market Realist1 hour ago

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.

  • 3 Terrible Reasons to Sell Pfizer Stock
    Motley Fool9 hours ago

    3 Terrible Reasons to Sell Pfizer Stock

    Pfizer's shares have been heating up, but now isn't the time to take profits. Here's why.

  • MYL Stock Down ~3% since Its Q2 2018 Results on August 8
    Market Realist9 hours ago

    MYL Stock Down ~3% since Its Q2 2018 Results on August 8

    The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $29.39 on August 15, 2017. Currently, MYL stock is trading above its 50-day moving average of $36.80 but below its 200-day moving average of $39.52. On August 8, MYL stock had declined as much as 7.2% on disappointing second-quarter results that missed analysts’ estimates.

  • Most Analysts Are Optimistic about Vertex Pharmaceuticals
    Market Realist10 hours ago

    Most Analysts Are Optimistic about Vertex Pharmaceuticals

    How Is Vertex Pharmaceuticals Positioned in August? On February 12, the FDA approved Vertex Pharmaceuticals’ (VRTX) Symdeko, which is the company’s third cystic fibrosis drug in the US market. Symdeko continues to witness a strong launch in the US market, and demand has risen across the entire range of eligible patients.

  • CNBC11 hours ago

    Stocks making the biggest moves premarket: WMT, JD, JCP, BA, CSCO & more

    Comparable-store sales at Walmart U.S. stores rose 4.5 percent from a year earlier, well above the consensus estimate of 2.4 percent. JD.com JD – The China-based internet retailer missed estimates on both the top and bottom lines in its second-quarter earnings report. Investors appear to be focusing on slowing revenue growth rates, with the second quarter's 31.2 percent growth well below the peak of about 60 percent registered in 2015.

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool11 hours ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • The Wall Street Journal11 hours ago

    [$$] Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration

    BioNTech said it will receive $120 million in upfront payments from Pfizer, along with up to $305 million in potential milestone payments. The Mainz, Germany, company said it will also receive up to double-digit tiered royalty payments on worldwide sales if the program reaches commercialization. BioNTech and Pfizer will jointly conduct research-and-development activities on mRNA-based flu vaccines, the companies said.

  • Financial Times16 hours ago

    [$$] Teva shares climb after FDA approves its generic EpiPen

    got a shot in the arm on Thursday from the long-awaited approval by US regulators of its generic version of Mylan’s EpiPen allergy injector. Teva’s New York-listed shares were up 6 per cent to $23.83 after the US Food and Drug Administration gave the go-ahead to the Israel-based company.

  • Reuters17 hours ago

    Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

    Pfizer (PFE.N) has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

  • Reuters17 hours ago

    Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance

    Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

  • Investor's Business Dailyyesterday

    FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%

    FANG stocks were down sharply in afternoon trading Wednesday, with shares of Netflix and Google parent Alphabet down more than 2%.

  • A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity
    Bloombergyesterday

    A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity

    People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.

  • TheStreet.comyesterday

    Buy Stocks That Are Down, Not Up, Here

    Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

  • 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
    Motley Foolyesterday

    3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

    An FDA approval is a big step, but some big challenges remain.

  • Novo Nordisk’s Biopharmaceuticals Segment: An Update
    Market Realistyesterday

    Novo Nordisk’s Biopharmaceuticals Segment: An Update

    Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.

  • What's Next for Spark Therapeutics
    Motley Foolyesterday

    What's Next for Spark Therapeutics

    This gene therapy biotech has its sights set on a second commercial-stage opportunity

  • Pfizer Expected to Report Robust EPS Rise in Fiscal 2018
    Market Realist2 days ago

    Pfizer Expected to Report Robust EPS Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.

  • How IBM’s Global Business Services Unit Is Doing
    Market Realist2 days ago

    How IBM’s Global Business Services Unit Is Doing

    IBM’s (IBM) Global Business Services unit, which represents ~21% of its total business, comprises its consulting, global business services, and application management offerings. In the last five quarters, the segment has grown 0.6% compounded annually, driven by improvement in its consulting business.

  • Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
    Market Realist2 days ago

    Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist3 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • How GlaxoSmithKline’s Valuation Compares with Peers’
    Market Realist3 days ago

    How GlaxoSmithKline’s Valuation Compares with Peers’

    Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017. 

  • 3 Beaten-Down Biotech Stocks: Can They Recover?
    Motley Fool4 days ago

    3 Beaten-Down Biotech Stocks: Can They Recover?

    Is there a light at the end of the tunnel?

  • GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript

    GLYC earnings call for the period ending June 30, 2018.